Biotech companies had to lower their pricing before floating on public markets.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
IPO floodgates unlikely to open after Ark floatation
Companies jostle for access to public markets
Related external links
Rights and permissions
About this article
Cite this article
Mitchell, P. IPO plans sour on both sides of the pond. Nat Biotechnol 22, 929–930 (2004). https://doi.org/10.1038/nbt0804-929
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0804-929
- Springer Nature America, Inc.
This article is cited by
-
Acquisition signals shift from US market
Nature Biotechnology (2005)
-
Early-stage biotechs raising more cash in Europe
Bioentrepreneur (2004)